Literature DB >> 22968782

Cerebral vein changes in relapsing-remitting multiple sclerosis demonstrated by three-dimensional enhanced T₂-weighted angiography at 3.0 T.

Chun Zeng1, Xuan Chen, Yongmei Li, Yu Ouyang, Fajin Lv, Reshiana Rumzan, Zhongping Wang.   

Abstract

OBJECTIVE: To investigate characteristics of the internal cerebral veins (ICVs) and their main tributaries and the deep medullary veins (DMVs) in patients with relapsing-remitting MS (RRMS) with enhanced T (2)-weighted angiography imaging (ESWAN).
METHODS: Fifty-three RRMS patients and 53 normal controls underwent conventional MRI and ESWAN. ESWAN venograms were created by performing minimum intensity projections of the phase images, and the resulting venograms were used to observe characteristic vascular changes, including scores of the ICVs and their main tributaries and manifestations of the DMVs. Two experienced radiologists analysed all data.
RESULTS: Patients showed decreased mean scores of the ICVs and their main tributaries compared with controls. The mean score in acute patients was higher than in stable patients. Furthermore, the DMVs diminished and shortened in 48 patients with longer disease duration, whereas the DMVs increased and elongated in 5 patients with shorter disease duration. The penetrating veins were well defined in 30 active lesions, whereas the veins were ill defined in 69 non-active lesions. Interestingly, well-defined penetrating veins were shown in 15 non-active lesions in the stable patients.
CONCLUSIONS: Enhanced T (2)-weighted MR angiography can detect cerebral vein characteristics in relapsing-remitting MS patients, which may provide important information on the pathogenesis of MS.

Entities:  

Mesh:

Year:  2012        PMID: 22968782     DOI: 10.1007/s00330-012-2637-5

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  38 in total

1.  Demonstrating the perivascular distribution of MS lesions in vivo with 7-Tesla MRI.

Authors:  E C Tallantyre; M J Brookes; J E Dixon; P S Morgan; N Evangelou; P G Morris
Journal:  Neurology       Date:  2008-05-27       Impact factor: 9.910

Review 2.  Primary progressive multiple sclerosis.

Authors:  A J Thompson; C H Polman; D H Miller; W I McDonald; B Brochet; X Filippi M Montalban; J De Sá
Journal:  Brain       Date:  1997-06       Impact factor: 13.501

Review 3.  Biotechnological agents for the immunotherapy of multiple sclerosis. Principles, problems and perspectives.

Authors:  R Hohlfeld
Journal:  Brain       Date:  1997-05       Impact factor: 13.501

4.  Elevated plasma endothelial microparticles in multiple sclerosis.

Authors:  A Minagar; W Jy; J J Jimenez; W A Sheremata; L M Mauro; W W Mao; L L Horstman; Y S Ahn
Journal:  Neurology       Date:  2001-05-22       Impact factor: 9.910

5.  Perfusion magnetic resonance imaging correlates of neuropsychological impairment in multiple sclerosis.

Authors:  Matilde Inglese; Sumita Adhya; Glyn Johnson; James S Babb; Laura Miles; Hina Jaggi; Joseph Herbert; Robert I Grossman
Journal:  J Cereb Blood Flow Metab       Date:  2007-05-02       Impact factor: 6.200

6.  White matter hemodynamic abnormalities precede sub-cortical gray matter changes in multiple sclerosis.

Authors:  Andrew W Varga; Glyn Johnson; James S Babb; Joseph Herbert; Robert I Grossman; Matilde Inglese
Journal:  J Neurol Sci       Date:  2009-01-31       Impact factor: 3.181

7.  Coagulation status and biochemical and inflammatory markers in multiple sclerosis.

Authors:  Fehime B Aksungar; Aynur E Topkaya; Zeynep Yildiz; Sevki Sahin; Ulku Turk
Journal:  J Clin Neurosci       Date:  2008-02-06       Impact factor: 1.961

8.  Microvascular abnormality in relapsing-remitting multiple sclerosis: perfusion MR imaging findings in normal-appearing white matter.

Authors:  Meng Law; Amit M Saindane; Yulin Ge; James S Babb; Glyn Johnson; Lois J Mannon; Joseph Herbert; Robert I Grossman
Journal:  Radiology       Date:  2004-06       Impact factor: 11.105

9.  Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria.

Authors:  Chris H Polman; Stephen C Reingold; Brenda Banwell; Michel Clanet; Jeffrey A Cohen; Massimo Filippi; Kazuo Fujihara; Eva Havrdova; Michael Hutchinson; Ludwig Kappos; Fred D Lublin; Xavier Montalban; Paul O'Connor; Magnhild Sandberg-Wollheim; Alan J Thompson; Emmanuelle Waubant; Brian Weinshenker; Jerry S Wolinsky
Journal:  Ann Neurol       Date:  2011-02       Impact factor: 10.422

10.  Lesion detection at seven Tesla in multiple sclerosis using magnetisation prepared 3D-FLAIR and 3D-DIR.

Authors:  Wolter L de Graaf; Jaco J M Zwanenburg; Fredy Visser; Mike P Wattjes; Petra J W Pouwels; Jeroen J G Geurts; Chris H Polman; Frederik Barkhof; Peter R Luijten; Jonas A Castelijns
Journal:  Eur Radiol       Date:  2011-08-27       Impact factor: 5.315

View more
  4 in total

1.  Quantification of Phase Values of Cerebral Microbleeds in Hypertensive Patients Using ESWAN MRI.

Authors:  L F Guo; J Geng; M H Qiu; C H Mao; C Liu; L Cui
Journal:  Clin Neuroradiol       Date:  2013-01-20       Impact factor: 3.649

2.  A Brain Region-Based Deep Medullary Veins Visual Score on Susceptibility Weighted Imaging.

Authors:  Ruiting Zhang; Ying Zhou; Shenqiang Yan; Genlong Zhong; Chang Liu; Yerfan Jiaerken; Ruirui Song; Xinfeng Yu; Minming Zhang; Min Lou
Journal:  Front Aging Neurosci       Date:  2017-08-08       Impact factor: 5.750

Review 3.  An Overview of Venous Abnormalities Related to the Development of Lesions in Multiple Sclerosis.

Authors:  E Mark Haacke; Yulin Ge; Sean K Sethi; Sagar Buch; Paolo Zamboni
Journal:  Front Neurol       Date:  2021-04-26       Impact factor: 4.003

4.  Optic radiations are thinner and show signs of iron deposition in patients with long-standing remitting-relapsing multiple sclerosis: an enhanced T2*-weighted angiography imaging study.

Authors:  Chun Zeng; Silin Du; Yongliang Han; Jialiang Fu; Qi Luo; Yayun Xiang; Xiaoya Chen; Tianyou Luo; Yongmei Li; Yineng Zheng
Journal:  Eur Radiol       Date:  2018-04-30       Impact factor: 5.315

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.